Evrysdi is owned by Genentech Inc.
Evrysdi contains Risdiplam.
Evrysdi has a total of 3 drug patents out of which 0 drug patents have expired.
Evrysdi was authorised for market use on 07 August, 2020.
Evrysdi is available in for solution;oral dosage forms.
Evrysdi can be used as treatment of spinal muscular atrophy.
Drug patent challenges can be filed against Evrysdi from 2024-08-07.
The generics of Evrysdi are possible to be released after 04 October, 2038.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US9586955||GENENTECH INC||Compounds for treating spinal muscular atrophy|| |
(9 years from now)
|US9969754||GENENTECH INC||Compounds for treating spinal muscular atrophy|| |
(12 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11534444||GENENTECH INC||Treatment of SMA|| |
(15 years from now)
|Orphan Drug Exclusivity (ODE)||May 27, 2029|
|New Chemical Entity Exclusivity (NCE)||Aug 7, 2025|
|New Patient Population (NPP)||May 27, 2025|
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 2024-08-07
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic